This activity is expired and is no longer available for CME credit.


Managing NSCLC and SCLC in the Community: What You Need to Know About the Latest Advances in Targeted Therapies and Immune Checkpoint Inhibitors

Author(s)/Faculty: Carlos Becerra, MD; Edward S. Kim, MD, FACP; Patrick A. Ott, MD, PhD
Release Date: 2/27/2020Expiration Date: 2/26/2021
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of novel diagnostic and therapeutic approaches that are tailored to individual patients. With continuing therapeutic advances, many tumor types now have several drug classes that, through tumor marker analysis, can be utilized for potential benefits in quality of life and survival. In this CME activity, experts in the field address clinical advances in non-small cell lung cancer and small cell lung cancer, and provide guidance for integrating newer therapeutic approaches into existing patient-management algorithms.